TRPM2 Channels: A Potential Therapeutic Target in Melanoma?

The transient receptor potential, the melastatin (TRPM) subfamily, which consists of eight known members, appears to have significant importance in melanoma progression, treatment, and prognosis. As several members were originally cloned from cancerous tissue, initial studies aimed towards identifyi...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-06, Vol.24 (13), p.10437
Main Authors: Foster, Hattie M, Carle, McKenzie N, Jira, Lukas R, Koh, David W
Format: Article
Language:English
Subjects:
Apoptosis
Biomarkers
Cancer
Cancer therapies
Care and treatment
Cell cycle
Cell growth
Development and progression
Growth factors
Health aspects
Humans
Kinases
Medical prognosis
Melanoma
Melanoma - drug therapy
Melanoma - genetics
Metastasis
Mutation
Oncology, Experimental
Physiology
Prognosis
Review
Roles
Skin
Skin cancer
Skin Neoplasms - drug therapy
Skin Neoplasms - genetics
Therapeutic targets
Transient receptor potential proteins
TRPM Cation Channels - genetics
TRPM Cation Channels - metabolism
Tumorigenesis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The transient receptor potential, the melastatin (TRPM) subfamily, which consists of eight known members, appears to have significant importance in melanoma progression, treatment, and prognosis. As several members were originally cloned from cancerous tissue, initial studies aimed towards identifying TRPM involvement in cancer progression and tumorigenesis. For relevance in skin cancer, previous research has shown roles for several TRPM members in skin cancer progression, growth, and patient prognosis. One unique member, TRPM2, appears to have notable therapeutic potential in the treatment of melanoma. Previous and recent studies have demonstrated increased TRPM2 expression levels in melanoma, as well as important roles for TRPM2 in melanoma growth, proliferation, and survival. TRPM2 is thus an emerging target in the treatment of melanoma, where TRPM2 antagonism may offer an additional treatment option for melanoma patients in the future.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms241310437